Advanced Oncotherapy (LSE:AVO) EBIT : £-26.92 Mil (TTM As of Jun. 2022)

View and export this data going back to 2006. Start your Free Trial

What is Advanced Oncotherapy EBIT?

Advanced Oncotherapy's earnings before interest and taxes (EBIT) for the six months ended in Jun. 2022 was £-13.54 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2022 was £-26.92 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Advanced Oncotherapy's annualized ROC % for the quarter that ended in Jun. 2022 was -19.79%. Advanced Oncotherapy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -42.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Advanced Oncotherapy's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2022 was -39.77%.

Advanced Oncotherapy EBIT Historical Data

The historical data trend for Advanced Oncotherapy's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advanced Oncotherapy EBIT Chart

Advanced Oncotherapy Annual Data

Trend

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

EBIT

Get a 7-Day Free Trial

-15.21

-21.83

-20.64

-21.13

-24.43

Advanced Oncotherapy Semi-Annual Data
	Dec12	Jun13	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22
EBIT	Get a 7-Day Free Trial															-9.78	-11.35	-11.05	-13.38	-13.54

Competitive Comparison of Advanced Oncotherapy's EBIT

For the Medical Devices subindustry, Advanced Oncotherapy's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Advanced Oncotherapy's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Advanced Oncotherapy's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Advanced Oncotherapy's EV-to-EBIT falls into.

Advanced Oncotherapy EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2022 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-26.92 Mil.

Advanced Oncotherapy (LSE:AVO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Advanced Oncotherapy's annualized ROC % for the quarter that ended in Jun. 2022 is calculated as:

	ROC % (Q: Jun. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2021 )	+	Invested Capital (Q: Jun. 2022 ))	/ count )
=	-27.072 * ( 1 - 0.48% )	/	( (133.142	+	139.133)	/ 2 )
=	-26.9420544	/	136.1375
=	-19.79 %

where

	Invested Capital		(Q: Dec. 2021 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	141.291	-	4.389	-	( 3.76	-	max(0, 16.118	-	30.73	+	3.76	))
=	133.142

	Invested Capital		(Q: Jun. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	153.173	-	11.533	-	( 2.507	-	max(0, 25.954	-	32.78	+	2.507	))
=	139.133

Note: The Operating Income data used here is two times the semi-annual (Jun. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Advanced Oncotherapy's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Jun. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2021		Q: Jun. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-27.072	/	( ( (41.055 + max(22.262, 0))	+	(43.961 + max(18.741, 0)) )	/	2 )
=	-27.072	/	( ( 63.317	+	62.702 )	/	2 )
=	-27.072	/	63.0095
=	-42.96 %

where Working Capital is:

	Working Capital		(Q: Dec. 2021 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.643	+	25.827	+	1.139)	-	(4.389	+	0	+	0.958)
=	22.262

	Working Capital		(Q: Jun. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.848	+	29.426	+	-0.00099999999999767)	-	(11.533	+	0	+	-0.00099999999999767)
=	18.741

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Jun. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Advanced Oncotherapy's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Jun. 2022 )
	=	-26.917	/	67.680
	=	-39.77 %

Advanced Oncotherapy EBIT Related Terms

Thank you for viewing the detailed overview of Advanced Oncotherapy's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Advanced Oncotherapy (LSE:AVO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Advanced Oncotherapy PLC (LSE:AVO) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

4 Tenterden Street, Third Floor, London, GBR, W1S 1TE

Website

https://www.avoplc.com

Advanced Oncotherapy PLC is active in the healthcare domain in the United Kingdom. As a medical care provider, its focus is to develop technologies to maximize the destructive effect of radiation on tumors whilst minimizing damage to healthy tissues. It develops an affordable proton-based radiotherapy system, using innovative and clinically effective technology, thereby contributing to curing critical unmet conditions. The company's only business segment is Proton Therapy.